Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
NASA's Artemis 2 moon launch seen from space | Space photo of the day for April 2, 2026 - 2The most effective method to Connect Successfully with Teachers in a Web based Setting
- 3No injuries after blast at pro-Israel centre in the Netherlands
- 4Study reveals links between global food systems, obesity, and climate change
- 5Going with Children: Tips for Tranquil Family Get-aways
- NASA satellite gazes into Medusa Pool | Space photo of the day for Dec. 24, 2025
- Israeli Chief of Staff declares new border with Gaza Strip
- Baidu robotaxi outage in Wuhan caused by 'system failure', police say
- Explainer-What Novo Nordisk's weight-loss pill approval means for company, patients
- Does physics say that free will doesn't exist?
- Why Tourists May Want To Reconsider Traveling To This Popular Spot In Italy In 2026
- Giude to Best Web based Learning Stage
- Before trips to Mars, we need better protection from cosmic rays
- OPEC’s No. 2 Producer Burns Its Own Gas—Then Buys Iran’s
